SAMHSA grants will encourage wider access to naloxone | Addiction Professional Magazine Skip to content Skip to navigation

SAMHSA grants will encourage wider access to naloxone

April 12, 2018
by Gary A. Enos, Editor
| Reprints

Methadone treatment programs and waivered buprenorphine prescribers are among those eligible for newly announced federal grants for development of best practices for the prescribing of the overdose reversal drug naloxone to high-need populations.

Up to five grantees will receive a maximum of $200,000 a year for five years under the Substance Abuse and Mental Health Services Administration's (SAMHSA's) Improving Access to Overdose Treatment grant program. Grant recipients will partner with other prescribers at the community level to develop best practices for prescribing overdose reversal drugs, and will engage in training that is targeted to prescribers and members of the public.

Eligibility is limited to federally qualified health centers (FQHCs), opioid treatment programs (OTPs), and practitioners waivered to prescribe buprenorphine.

The application deadline is June 4. Click here for the grant program announcement.

The Summits for Clinical Excellence bring together thought leaders on cutting-edge topics in multi-day national and regional conferences. Summits on mindfulness, trauma, process addiction, and shame appeal particularly to private practice behavioral healthcare professionals. Other Summits address the national opioid crisis from a regional perspective and engage a diverse group of stakeholders.

June 25-26, 2018 Pittsburgh — The Opioid Crisis: The Clinician's Role and Treatment Practices